The global gastrointestinal diagnostics market size is expected to reach USD 6.56 billion by 2030, registering a CAGR of 4.3% from 2025 to 2030. Rising awareness about gastrointestinal disorders and a surge in gastrointestinal disorder testing are the major factors driving the market. Moreover, technological advancements in gastrointestinal infection testing are expected to cater to the market demand. For instance, in May 2022, QIAGEN launched QIAstat-Dx Rise, which is capable of providing results in a span of one hour for multiple diseases.
The increasing trend of a sedentary lifestyle, lack of exercise, unhealthy eating habits, and a higher prevalence of obesity are anticipated to fuel GI diagnostics market growth. According to the CDC, the prevalence of obesity among people in the U.S. is between 30-40%. States such as Alabama, Alaska, and Arizona have the highest prevalence of obesity in the U.S. Obesity is associated with GI diseases such as gastroesophageal reflux disease, diarrhea, gastric cancer, and others. Hence, it is expected to impetus market growth.
Technological advancements associated with gastrointestinal diagnostics for early diagnosis and efficient testing are expected to augment market growth during the forecast period. For instance, in March 2022, Luminex Corporation obtained a CE mark for its NxTAGxMAP GI Pathogen Panel. This test is a detailed multiplex test that detects nucleic acids from the 16 most clinically relevant viral, parasitic, and bacterial pathogens in stool samples. Moreover, the test is capable of providing results on the same day and can run 96 samples at a time.
Moreover, the presence of organizations involved in increasing awareness regarding gastrointestinal disorders is expected to facilitate market expansion. For instance, organizations such as the Gastrointestinal Society (Canadian Society of Intestinal Research) and the International Foundation for Gastrointestinal Disorders are actively involved in promoting gastrointestinal health and broadening the understanding of GI disorders, thereby augmenting market growth.
Furthermore, various strategic initiatives undertaken by market players to strengthen their product portfolio and expand global footprints are likely to provide lucrative growth opportunities for the market. For instance, in November 2021, The Life Raft Group and Bayer Pharmaceuticals announced a research collaboration for broadening access to genomic testing for GI stromal tumor patients. The aim of this collaboration is to advance precision medicine and improve genetic testing to identify patients in the U.S.
In addition, in June 2021, Prometheus Laboratories, Inc. announced an agreement with MultiPlan for accessing specialized gastrointestinal testing. Prometheus offered its breakthrough testing solutions to improve the outcome of GI disorders. This agreement has allowed the testing service of Prometheus to reach the maximum number of customers.
This product will be delivered within 1-3 business days.
The increasing trend of a sedentary lifestyle, lack of exercise, unhealthy eating habits, and a higher prevalence of obesity are anticipated to fuel GI diagnostics market growth. According to the CDC, the prevalence of obesity among people in the U.S. is between 30-40%. States such as Alabama, Alaska, and Arizona have the highest prevalence of obesity in the U.S. Obesity is associated with GI diseases such as gastroesophageal reflux disease, diarrhea, gastric cancer, and others. Hence, it is expected to impetus market growth.
Technological advancements associated with gastrointestinal diagnostics for early diagnosis and efficient testing are expected to augment market growth during the forecast period. For instance, in March 2022, Luminex Corporation obtained a CE mark for its NxTAGxMAP GI Pathogen Panel. This test is a detailed multiplex test that detects nucleic acids from the 16 most clinically relevant viral, parasitic, and bacterial pathogens in stool samples. Moreover, the test is capable of providing results on the same day and can run 96 samples at a time.
Moreover, the presence of organizations involved in increasing awareness regarding gastrointestinal disorders is expected to facilitate market expansion. For instance, organizations such as the Gastrointestinal Society (Canadian Society of Intestinal Research) and the International Foundation for Gastrointestinal Disorders are actively involved in promoting gastrointestinal health and broadening the understanding of GI disorders, thereby augmenting market growth.
Furthermore, various strategic initiatives undertaken by market players to strengthen their product portfolio and expand global footprints are likely to provide lucrative growth opportunities for the market. For instance, in November 2021, The Life Raft Group and Bayer Pharmaceuticals announced a research collaboration for broadening access to genomic testing for GI stromal tumor patients. The aim of this collaboration is to advance precision medicine and improve genetic testing to identify patients in the U.S.
In addition, in June 2021, Prometheus Laboratories, Inc. announced an agreement with MultiPlan for accessing specialized gastrointestinal testing. Prometheus offered its breakthrough testing solutions to improve the outcome of GI disorders. This agreement has allowed the testing service of Prometheus to reach the maximum number of customers.
Gastrointestinal Diagnostics Market Report Highlights
- On the basis of test type, the endoscopy segment held the largest share in 2024 owing to rising demand for minimally invasive procedures
- Based on technology, the PCR accounted for the second-largest share in 2024 due to the availability of a robust product portfolio and rising product launches
- The infection application segment held the largest share in 2024 owing to the higher incidence of GI infections and the surge in awareness
- On the basis of test location, the central laboratories segment held the largest share in 2024. The point-of-care segment is anticipated to register the fastest growth rate throughout the forecast period
- Asia Pacific is expected to exhibit the fastest growth rate over the forecast period due to the rising investments by market players and increasing research activities in the region
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments
- Competitive Landscape: Explore the market presence of key players worldwide
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
The leading players in the Gastrointestinal Diagnostics market include:
- BIOMERIEUX
- F. Hoffmann-La Roche Ltd.
- Abbott
- Beckman Coulter, Inc.
- DiaSorin S.p.A
- Siemens Healthineers AG
- QIAGEN
- Meridian Bioscience
- Hologic, Inc.
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Gastrointestinal Diagnostics Market Variables, Trends & Scope
Chapter 4. Gastrointestinal Diagnostics Market: Test Type Estimates & Trend Analysis
Chapter 5. Gastrointestinal Diagnostics Market: Technology Estimates & Trend Analysis
Chapter 6. Gastrointestinal Diagnostics Market: Application Estimates & Trend Analysis
Chapter 7. Gastrointestinal Diagnostics Market: Test Location Estimates & Trend Analysis
Chapter 8. Gastrointestinal Diagnostics Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- BIOMERIEUX
- F. Hoffmann-La Roche Ltd.
- Abbott
- Beckman Coulter, Inc.
- DiaSorin S.p.A
- Siemens Healthineers AG
- QIAGEN
- Meridian Bioscience
- Hologic, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | October 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.08 Billion |
| Forecasted Market Value ( USD | $ 6.56 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 9 |
